Dataset Information


Is there a difference in rhythm outcome between patients undergoing first line versus second line paroxysmal atrial fibrillation ablation?

ABSTRACT: BACKGROUND:Catheter ablation of atrial fibrillation (AF) is an established second line therapy for patients with symptomatic paroxysmal AF (PAF) and may be considered as a first line therapy in selected patients who are highly symptomatic, considering patient choice, benefit, and risk, according to recent guidelines. Our study investigated whether a first line vs. second line ablation approach may result in improved sinus rhythm maintenance after ablation. METHODS:A total of 153 patients undergoing pulmonary vein isolation for PAF were included in the study (age 55±12 years, 29% female). Seventy-nine patients underwent first line AF ablation and 74 patients underwent second line AF ablation after failed antiarrhythmic drug therapy. There was no significant difference in baseline characteristics such as age, history of AF, left atrial size or LVEF between groups. Success was defined as atrial tachyarrhythmia free survival during a 12-month follow-up by means of serial ECG Holter monitoring. RESULTS:There was no significant difference in cumulative arrhythmia-free survival between those patients who received AF ablation as a first or second line therapy. Single procedure success was 78% in the first line group vs. 81% in the second line group; multiple procedure success was 90 vs. 91%, (n.s.). Complication rate was 1.3% vs. 1.4% (n.s.). CONCLUSION:Success of AF ablation did not differ between patients who receive ablation as first vs. second line therapy. Based on these data, a trial of AAD therapy before AF ablation may be justified in most patients with symptomatic PAF eligible for rhythm control.

SUBMITTER: Manninger M 

PROVIDER: S-EPMC6285381 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7591346 | BioStudies
2018-01-01 | S-EPMC6533809 | BioStudies
2020-01-01 | S-EPMC7536288 | BioStudies
2016-01-01 | S-EPMC5052470 | BioStudies
2019-01-01 | S-EPMC6706423 | BioStudies
2020-01-01 | S-EPMC7661657 | BioStudies
2020-01-01 | S-EPMC7411193 | BioStudies
2017-01-01 | S-EPMC5633714 | BioStudies
2018-01-01 | S-EPMC6010015 | BioStudies
1000-01-01 | S-EPMC5975575 | BioStudies